frontline afatinib in egfr-mutant nsclc
Published 9 years ago • 730 plays • Length 4:09Download video MP4
Download video MP3
Similar videos
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
8:11
advances in frontline therapy for egfr nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
1:35
dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
9:31
frontline treatment for egfr nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
7:08
emerging data in egfr-mutant lung cancer
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
4:06
afatinib in patients with uncommon egfr mutations